Clinical Study
Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers
Table 3
Mean pharmacokinetic parameters of sulindac, sulindac sulfide, and sulindac sulfone for FMO3
HHDD (
) and FMO3
hhdd (
).
| | FMO3 HHDD | FMO3 hhdd |
| Sulindac | | | (ng·h·mL−1) | 27.93 ± 8.85 | 41.88 ± 17.37 | (ng·h·mL−1) | 22.82 ± 7.87 | 35.16 ± 9.60 | (ng·mL−1) | 6.95 ± 3.28 | 11.87 ± 4.80 | (h) | 1.82 ± 1.07 | 1.64 ± 0.48 | (h) | 4.01 ± 1.24 | 4.46 ± 1.30 | Sulindac sulfide | | | (ng·h·mL−1) | 43.69 ± 15.23 | 49.67 ± 25.92 | (ng·h·mL−1) | 32.93 ± 15.59 | 32.22 ± 13.56 | (ng·mL−1) | 32.93 ± 15.59 | 32.22 ± 13.56 | (h) | 2.43 ± 1.59 | 3.07 ± 1.17 | (h) | 10.18 ± 3.28 | 9.77 ± 3.97 | Sulindac sulfone | | | (ng·h·mL−1) | 65.64 ± 16.98 | 65.69 ± 24.34 | (ng·h·mL−1) | 48.18 ± 0.31 | 42.76 ± 14.67 | (ng·mL−1) | 3.43 ± 1.19 | 3.69 ± 1.61 | (h) | 2.57 ± 0.98 | 2.86 ± 1.07 | (h) | 12.19 ± 2.44 | 10.62 ± 2.31 |
|
|
, maximum plasma concentration; AUC, area under plasma concentration-time curve; , time of maximum plasma concentration; , half-life of elimination. .
|